2022
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Ventura-Cots M, Argemi J, Jones PD, Lackner C, Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carrillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, Straub BK, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut 2022, 71: 1856-1866. PMID: 34992134, PMCID: PMC11034788, DOI: 10.1136/gutjnl-2021-324295.Peer-Reviewed Original ResearchConceptsAlcohol-related liver diseaseAlcohol-related hepatitisAH patientsLiver diseaseAlcohol intakeDuctular reactionGamma-glutamyl transferase levelsProfound liver failureSevere neutrophil infiltrationWorse liver functionObservational multicentre studyOne-year mortalityBile acid metabolismMallory-Denk bodiesRNA microarray analysisNeutrophil infiltrationProspective cohortRetrospective cohortAdvanced fibrosisLiver failureMulticentre studySteatosis gradeLiver functionPericellular fibrosisSevere fibrosis
2021
Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
Yan K, Hung A, Parmer C, Yang H, Jain D, Lim B, Goodman AL, Garcia‐Tsao G. Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites. Hepatology Communications 2021, 5: 1507-1517. PMID: 34510838, PMCID: PMC8435275, DOI: 10.1002/hep4.1740.Peer-Reviewed Original ResearchHigher serum albuminBacterial translocationObeticholic acidEnd of studyAspartate aminotransferaseLymph nodesIntestinal microbiomeIntestinal contentsSemisynthetic bile acidMesenteric lymph nodesEnd of treatmentCarbon tetrachloride inhalationExtra-intestinal sitesLower aspartate aminotransferaseFurther decompensationLiver injuryLiver functionPolymerase chain reactionExperimental cirrhosisPathogenic bacteriaCirrhosisHepatocyte deathDay 1Bile acidsPlacebo
2017
Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis
Albillos A, Zamora J, Martínez J, Arroyo D, Ahmad I, De‐la‐Peña J, Garcia‐Pagán J, Lo G, Sarin S, Sharma B, Abraldes JG, Bosch J, Garcia‐Tsao G, Cooperation O. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis. Hepatology 2017, 66: 1219-1231. PMID: 28543862, PMCID: PMC5605404, DOI: 10.1002/hep.29267.Peer-Reviewed Original ResearchConceptsChild B/CPrevious variceal bleedingCombination therapyVariceal bleedingCirrhosis severityChild APrognostic stageRecurrent variceal hemorrhageAdvanced liver failureEndoscopic variceal ligationOutcome of therapyVariceal hemorrhageLiver failureVariceal ligationLiver functionPatientsPatient careVaricealTherapyPatient dataMortalityTrialsCirrhosisBleedingProphylaxis
2011
Intensive care of the patient with cirrhosis
Olson JC, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia‐Tsao G, Kamath PS. Intensive care of the patient with cirrhosis. Hepatology 2011, 54: 1864-1872. PMID: 21898477, DOI: 10.1002/hep.24622.Peer-Reviewed Original ResearchConceptsMultiple organ failureIntensive care unitCare unitOrgan failureLiver functionSignificant survival benefitPresence of infectionFurther deteriorationQuality of lifeNumber of organsLiver support systemsAlcoholic hepatitisLiver transplantationVariceal hemorrhageAcute deteriorationCommon organLiver dysfunctionSurvival benefitViral hepatitisIll patientsIntensive careCritical carePatientsHigh mortalityTeam approachObesity is an independent risk factor for clinical decompensation in patients with cirrhosis
Berzigotti A, Garcia‐Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia‐Pagan J, Patch D, Matloff DS, Groszmann RJ, Group T. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011, 54: 555-561. PMID: 21567436, PMCID: PMC3144991, DOI: 10.1002/hep.24418.Peer-Reviewed Original ResearchConceptsBody mass indexClinical decompensationPortal pressureBMI groupsNormal body mass indexRole of obesityChronic viral hepatitisIndependent risk factorSubset of patientsValuable therapeutic measureActuarial probabilityCompensated cirrhosisViral hepatitisAggressive courseIndependent predictorsMass indexRandomized trialsLiver functionPatient populationRisk factorsTherapeutic measuresStudy populationCirrhosisTreatment groupsPatients
1990
Role of the distal splenorenal shunt in management of variceal bleeding in Latin America
Orozco H, Mercado M, Takahashi T, García-Tsao G, Guevara L, Ortíz J, Hernández-Cendejas A, Tielve M. Role of the distal splenorenal shunt in management of variceal bleeding in Latin America. The American Journal Of Surgery 1990, 160: 86-89. PMID: 2368881, DOI: 10.1016/s0002-9610(05)80874-8.Peer-Reviewed Original ResearchConceptsSelective shuntWarren shuntPortal hypertensionSplenorenal shuntDistal splenorenal shuntNormal liver functionTreatment of choiceSplenocaval shuntOperative mortalityVariceal bleedingShunt thrombosisVenous diameterLiver functionShuntChild classHypertensionThrombosisPatientsTreatmentYearsRegular basisLatin American countriesBleedingSchistosomiasisMortalitySelective portal-systemic shunts for bleeding portal hypertension.
Orozco H, Mercado M, Takahashi T, García-Tsao G, Guevara L, Hernandez-Ortiz J, Tielve M. Selective portal-systemic shunts for bleeding portal hypertension. Revista De Investigación Clínica 1990, 42 Suppl: 165-9. PMID: 19256158.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHumansHypersplenismHypertension, PortalKaplan-Meier EstimateLiver CirrhosisMaleMiddle AgedPatient SelectionPortal VeinPortasystemic Shunt, SurgicalPostoperative ComplicationsRecurrenceRetrospective StudiesSeverity of Illness IndexThrombosisYoung AdultConceptsSelective shuntPortal hypertensionOperative mortalityChild A groupChild A patientsGlobal operative mortalityPortal-systemic shuntsGood liver functionTreatment of choiceElective fashionSplenocaval shuntWarren shuntPostoperative periodA patientsShunt thrombosisLiver functionHypertensionShuntPatientsA groupThrombosisMortalityYear periodTreatmentYears
1989
Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients
Vorobioff J, Garcia‐Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio R, Hernandez‐Ortiz J. Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989, 9: 88-91. PMID: 2908873, DOI: 10.1002/hep.1840090114.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientPortal hypertensive patientsVenous pressure gradientMean arterial pressureHypertensive patientsCardiac indexArterial pressureMean baseline hepatic venous pressure gradientBaseline hepatic venous pressure gradientLong-term hemodynamic effectsAcute hemodynamic studyChronic oral administrationHepatic venous pressurePoor liver functionAlcoholic cirrhosisPortal hypertensionReceptor blockersHemodynamic effectsPortal pressurePortosystemic encephalopathyChronic treatmentVenous pressureLiver functionMean doseHemodynamic studies